Stiripentol(Diacomit)

On August 20, 2018, the FDA approved the prescription drug stiripentol for marketing, which targets the GABA receptor and the CYP450 enzyme system (CYP3A4, CYP2C19). It should be used strictly in accordance with medical advice.

Target of Action

GABA receptors, CYP450 enzyme system (CYP3A4, CYP2C19)

Dosage and Administration

Route and frequency of administration of Stiripentol: Oral administration, 50 mg/kg daily, administered in 2 or 3 divided doses..

Dosage adjustment of Stiripentol should be made according to the patient’s actual condition. For specific circumstances, contact a doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Stiripentol

Adverse Reactions

Common side effects: Drowsiness, decreased appetite, etc.

Serious side effects: Neutropenia, thrombocytopenia, etc.

Reference Article: Side Effects of Stiripentol

Use in Special Populations

Pregnancy: There is currently insufficient information regarding the risk of using DIACOMIT in pregnant women.

Lactation: The benefits of breastfeeding, the importance of stiripentol to the mother, and the potential adverse effects of the drug or the mother’s underlying disease on the breastfed infant should be comprehensively considered.

Daily Precautions

1. Patients or caregivers should be informed that stiripentol should be taken with meals: The capsules should be swallowed whole with a glass of water during meals and must not be broken or opened; stiripentol oral suspension powder should be mixed well in a glass of water and taken immediately during meals.

2. Risk of drowsiness: Dose reduction of concomitant clobazam may be required.

3. Patients should be informed of the importance of avoiding alcohol during stiripentol treatment.

from FDA，2022.07